Rep. Gilbert Ray Cisneros, Jr. Sells Off Shares of Boston Scientific Corporation (NYSE:BSX)

Representative Gilbert Ray Cisneros, Jr. (D-California) recently sold shares of Boston Scientific Corporation (NYSE:BSX). In a filing disclosed on August 14th, the Representative disclosed that they had sold between $1,001 and $15,000 in Boston Scientific stock on July 31st. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of W.R. Berkley (NYSE:WRB) on 7/31/2025.
• Purchased $1,001 – $15,000 in shares of CoStar Group (NASDAQ:CSGP) on 7/31/2025.
• Purchased $1,001 – $15,000 in shares of Dayforce (NYSE:DAY) on 7/31/2025.
• Sold $1,001 – $15,000 in shares of Medpace (NASDAQ:MEDP) on 7/24/2025.
• Sold $1,001 – $15,000 in shares of Avantor (NYSE:AVTR) on 7/23/2025.
• Purchased $1,001 – $15,000 in shares of Revvity (NYSE:RVTY) on 7/23/2025.
• Purchased $1,001 – $15,000 in shares of Gulfport Energy (NYSE:GPOR) on 7/18/2025.
• Purchased $1,001 – $15,000 in shares of Ultragenyx Pharmaceutical (NASDAQ:RARE) on 7/15/2025.
• Purchased $1,001 – $15,000 in shares of PTC (NASDAQ:PTC) on 7/9/2025.
• Purchased $1,001 – $15,000 in shares of Robinhood Markets (NASDAQ:HOOD) on 7/9/2025.

Boston Scientific Price Performance

BSX opened at $103.06 on Tuesday. Boston Scientific Corporation has a one year low of $77.71 and a one year high of $108.94. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.37 and a quick ratio of 0.82. The company’s 50 day simple moving average is $103.62 and its 200-day simple moving average is $102.09. The stock has a market capitalization of $152.71 billion, a P/E ratio of 61.35, a price-to-earnings-growth ratio of 2.48 and a beta of 0.66.

Boston Scientific (NYSE:BSX) last released its quarterly earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 EPS for the quarter, beating the consensus estimate of $0.72 by $0.03. Boston Scientific had a net margin of 13.55% and a return on equity of 19.21%. The business had revenue of $5.06 billion for the quarter, compared to analysts’ expectations of $4.89 billion. During the same period in the prior year, the firm earned $0.62 earnings per share. Boston Scientific’s revenue was up 22.8% compared to the same quarter last year. Sell-side analysts anticipate that Boston Scientific Corporation will post 2.85 earnings per share for the current fiscal year.

Insider Buying and Selling at Boston Scientific

In related news, Director Edward J. Ludwig sold 4,000 shares of the firm’s stock in a transaction on Friday, July 25th. The shares were sold at an average price of $106.03, for a total transaction of $424,120.00. Following the sale, the director directly owned 18,479 shares in the company, valued at $1,959,328.37. This trade represents a 17.79% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP Arthur C. Butcher sold 17,313 shares of Boston Scientific stock in a transaction on Friday, August 1st. The shares were sold at an average price of $104.63, for a total transaction of $1,811,459.19. Following the completion of the sale, the executive vice president owned 23,600 shares in the company, valued at $2,469,268. The trade was a 42.32% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 345,029 shares of company stock valued at $35,976,603 over the last quarter. 0.50% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Boston Scientific

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc. raised its holdings in shares of Boston Scientific by 1.9% during the second quarter. Vanguard Group Inc. now owns 137,134,110 shares of the medical equipment provider’s stock worth $14,729,575,000 after acquiring an additional 2,545,381 shares during the period. State Street Corp raised its holdings in shares of Boston Scientific by 1.1% during the second quarter. State Street Corp now owns 65,191,864 shares of the medical equipment provider’s stock worth $7,002,258,000 after acquiring an additional 713,379 shares during the period. Geode Capital Management LLC raised its holdings in shares of Boston Scientific by 2.0% during the second quarter. Geode Capital Management LLC now owns 32,424,982 shares of the medical equipment provider’s stock worth $3,466,320,000 after acquiring an additional 622,602 shares during the period. Capital World Investors raised its holdings in shares of Boston Scientific by 28.7% during the fourth quarter. Capital World Investors now owns 27,899,903 shares of the medical equipment provider’s stock worth $2,492,041,000 after acquiring an additional 6,216,199 shares during the period. Finally, DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main raised its holdings in shares of Boston Scientific by 2.5% during the fourth quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 22,312,967 shares of the medical equipment provider’s stock worth $1,992,994,000 after acquiring an additional 554,388 shares during the period. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

BSX has been the topic of several research analyst reports. UBS Group increased their price target on shares of Boston Scientific from $130.00 to $135.00 and gave the company a “buy” rating in a research note on Thursday, July 24th. Wells Fargo & Company increased their price target on shares of Boston Scientific from $118.00 to $124.00 and gave the company an “overweight” rating in a research note on Thursday, July 24th. Robert W. Baird increased their price target on shares of Boston Scientific from $117.00 to $123.00 and gave the company an “outperform” rating in a research note on Thursday, July 24th. Truist Financial raised their price objective on shares of Boston Scientific from $120.00 to $125.00 and gave the company a “buy” rating in a research note on Thursday, July 24th. Finally, Erste Group Bank raised shares of Boston Scientific to a “strong-buy” rating in a report on Thursday, May 8th. Two equities research analysts have rated the stock with a hold rating, twenty-two have given a buy rating and three have given a strong buy rating to the company. According to MarketBeat.com, Boston Scientific currently has an average rating of “Buy” and an average price target of $117.50.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.